Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Duggan is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
Tralokinumab (Adtralza®) is a human IgG4 monoclonal
antibody being developed by LEO Pharma for the treatment of atopic
dermatitis. The T-helper
cytokine IL-13 is thought to play a key role in the pathogenesis of atopic
dermatitis. Tralokinumab specifically binds with high affinity to IL-13, inhibiting
its interaction with the IL-13 receptor and thereby neutralising the biological
activity of the cytokine. Based on results from the ECZTRA 1-3 trials,
tralokinumab has recently been approved in the EU for
the treatment of moderate-to-severe atopic dermatitis in adult patients who are
candidates for systemic therapy.
This article summarizes the milestones in the development of tralokinumab
leading to this first approval for atopic dermatitis.
© Springer Nature Switzerland AG 2021